Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Total Non-current Liabilities
All obligations due after more than one year.
Sionna Therapeutics, Inc.NASDAQ: SION
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 15.8% from a year ago
Total non-current liabilities stood at $7.06M at the end of Q1 FY2026, down 15.8% from a year earlier and down 4.8% from the prior quarter. Over 3 fiscal years it compounded at -63.2% a year.
Context
- Total non-current liabilities amounted to 2.3% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -15.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.41M USD
- Year-over-year change
- -97.8%
- 3-year CAGR
- -63.2%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.41M | -97.8% |
| FY2024 | 2024-12-31 | 339.05M | +113.5% |
| FY2023 | 2023-12-31 | 158.79M | +6.5% |
| FY2022 | 2022-12-31 | 149.04M | — |
Total Non-current Liabilities vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 total non-current liabilities of $7.06M is the lowest of the 11 companies compared; the peer median is $161.61M.
- Its year-over-year change of -15.8% is the lowest of 11, against a peer median of +32.0%.
- Total non-current liabilities amounts to 2.3% of total assets for SION, versus a peer median of 19.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $756.7M | +2052.0% | -16.0% | 64.3% | |
| Sep 2026 | $366.89M | +13.5% | +19.8% | 24.5% | |
| Jun 2026 | $295.86M | +1.5% | +104.8% | 79.8% | |
| Mar 2026 | $260.41M | +1.9% | +4.9% | 66.4% | |
| Mar 2026 | $246.32M | +30.5% | +111.2% | 48.8% | |
| Jun 2026 | $76.91M | +0.3% | +38.4% | 14.4% | |
| Mar 2026 | $56.77M | +156.3% | -10.9% | 13.5% | |
| Mar 2026 | $27.78M | +33.5% | -1.3% | 2.7% | |
| Sep 2026 | $11.55M | +219.7% | -15.2% | 1.6% | |
| Sep 2026 | $10.26M | +155.6% | +296.2% | 2.0% | |
| Mar 2026 | $7.06M | -15.8% | -63.2% | 2.3% | |
| Peer median (excluding SION) | $161.61M | +32.0% | +12.3% | 19.4% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.